- Stocks
- Pharma & Healthcare
- Aashka Hospital
Aashka Hospital share price
NSE: AASHKAPharma & HealthcareMedical Care Facilities
Aashka Hospital at a glance
With a market capitalisation of ₹190 Cr, it ranks 2305th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 3.2% in FY26. Promoters held 61.33% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹190 CrRank 2305 on NSE
- Price to book
- 1.34×FY26
- EPS (TTM)
- ₹0.00to Q4 FY26
- ROE
- 3.2%FY26
- ROCE
- 4.1%FY26
- Debt to equity
- 0.08FY26
- Net profit margin
- 14.5%FY26
- Book value / share
- ₹44.13FY26
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Aashka Hospital quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | — | — | — | — | — | — | — | −233.3% |
| Net margin | — | — | — | — | — | — | — | — |
| EPS | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
Aashka Hospital financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹40 Cr | ₹19 Cr | ₹23 Cr | ₹23 Cr | — |
| Operating profit | ₹3 Cr | −₹3 Cr | ₹3 Cr | ₹3 Cr | — |
| Net profit | ₹2 Cr | −₹3 Cr | ₹2 Cr | ₹3 Cr | — |
| EPS (₹) | ₹1.12 | −₹1.10 | ₹1.01 | ₹1.40 | — |
| Cash from operations | −₹63 Cr | ₹4 Cr | ₹7 Cr | ₹9 Cr | — |
| Total debt | ₹17 Cr | ₹16 Cr | ₹8 Cr | ₹6 Cr | ₹6 Cr |
| Shareholders' equity | ₹97 Cr | ₹94 Cr | ₹96 Cr | ₹100 Cr | ₹103 Cr |
Aashka Hospital shareholding pattern
| Holder | 30 Sep 2023 | 31 Mar 2024 | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.28% | 61.28% | 61.28% | 61.28% | 61.33% | 61.33% |
| Non-institutions | 38.72% | 38.72% | 38.72% | 38.72% | 38.67% | 38.67% |
Aashka Hospital vs peers
The listed Pharma & Healthcare companies nearest to Aashka Hospital by market capitalisation.
Ask anything about Aashka Hospital
Pivot answers on the live chart with evidence you can check, and tests strategies against AASHKA's own history. Try: “Why has AASHKA moved over the last three months?” · “Backtest a 50-day moving-average crossover on AASHKA over five years” · “Compare AASHKA with CORALAB on margins and valuation”
Frequently asked questions about Aashka Hospital
What is the market cap of Aashka Hospital?
Aashka Hospital's market capitalisation is ₹190 Cr (₹190 Cr) at the 21 Oct 2026 close, ranking 2305th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Aashka Hospital?
Return on equity was 3.2% in FY26 and return on capital employed was 4.1% in FY26 (standalone figures).
Is Aashka Hospital a debt-free company?
No. Aashka Hospital's debt-to-equity ratio was 0.08 in FY26, with total debt of ₹7 Cr.
What is the shareholding pattern of Aashka Hospital?
As of 31 Mar 2026: promoters 61.33%, non-institutions 38.67%.
Who are Aashka Hospital's competitors?
The listed Pharma & Healthcare companies closest to Aashka Hospital by market cap are Coral Labs, OXYGENTA PHARMA, Accretion Nutra, Brooks Laboratories, Earkart and Novelix Pharma.
Is Aashka Hospital a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aashka Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AASHKA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text